# A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Clinical trial · Eli Lilly and Company

- Archive id: nct:NCT04184622
- Published: 2019-12-03
- Venue: ClinicalTrials.gov
- ClinicalTrials.gov: https://clinicaltrials.gov/study/NCT04184622
- Source URL: https://clinicaltrials.gov/study/NCT04184622
- Provenance: clinicaltrials

## Abstract

This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.

_Abstract reproduced under ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters._

## Trial details

- acronym: SURMOUNT-1
- status: COMPLETED
- phase: PHASE3
- study type: INTERVENTIONAL
- enrollment: 2539
- sponsor: Eli Lilly and Company
- conditions: Overweight; Obesity
- interventions: DRUG: Tirzepatide; DRUG: Placebo
- start date: 2019-12-04
- start date type: ACTUAL
- primary completion date: 2022-04-01
- has results: true
- data source: ClinicalTrials.gov
- data processed: 2026-10-29T09:00:05
- modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.